Monday, 15 October 2018

Assessing the Risk of Osteoporosis at the Earlier

Assessing the Risk of Osteoporosis at the Earlier

Brittle bone or osteoporosis is a symptomless and long-running disease caused by the gradual deterioration of bone density. If it is not detected and treated at the earlier, the bone will grow weaker and get more brittle, thus more susceptible to fracture. Bone fracture occurring from osteoporosis can cause pain and even death. Furthermore, this condition requires high-cost treatment.

Osteoporosis risk assessment will be better if supplemented with bone density tests. One of those tests is bone biochemical marker analysis. Biochemical marker analysis is a blood test capable of assessing the formation and deterioration of bone as well as the balance between those two.

If the resorption or breaking down process of bone is more dominant than the formation of new bone, the bone density will decrease rapidly and the risk of having osteoporosis in the future will occur. Bone biochemical marker analysis includes C-Telopeptide (CTx) and N-MID Osteocalcin. C-Telopeptide (CTx) analysis functions as an assessment for the breaking down of bone, while N-MID Osteocalcin can assess the formation of bone.

If the result of bone biochemical marker analysis indicates that you have a high risk of osteoporosis, consult a doctor. If required, the doctor will ask you to take a follow-up test such as the bone mineral density (BMD) to determine the density level and condition of the bone as well as to analyze the risk of osteoporosis.

Love your bone and keep it healthy. In order to do so, you can take the following three measures: daily weight exercise and muscular training, balance diet with sufficient amount of calcium and vitamin D, and also laboratory analysis to figure out the biochemical condition of the bone.